Back to top
more

Teleflex (TFX)

(Real Time Quote from BATS)

$116.25 USD

116.25
134,856

+0.36 (0.31%)

Updated Aug 4, 2025 02:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures

by Zacks Equity Research

With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.

Zacks Equity Research

Teleflex (TFX) Picked for Vizient Innovative Technology Exchange

by Zacks Equity Research

Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.

Zacks Equity Research

Teleflex (TFX) New Survey Highlights BPH Impact Life Quality

by Zacks Equity Research

Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).

Zacks Equity Research

Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System

by Zacks Equity Research

Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up

by Zacks Equity Research

Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.

Zacks Equity Research

Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).

Zacks Equity Research

Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes

by Zacks Equity Research

Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval

by Zacks Equity Research

Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.

Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod

by Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.

Zacks Equity Research

Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up

by Zacks Equity Research

Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.

Zacks Equity Research

Teleflex (TFX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Teleflex (TFX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 4.04% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sientra (SIEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sientra (SIEN) delivered earnings and revenue surprises of -137.50% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays

by Zacks Equity Research

Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down

by Zacks Equity Research

Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.

Zacks Equity Research

Teleflex (TFX) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Teleflex (TFX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Teleflex (TFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.